{"id":7816,"date":"2022-04-04T00:30:00","date_gmt":"2022-04-04T00:30:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/3712429_AE12429_0"},"modified":"2022-04-04T00:30:00","modified_gmt":"2022-04-04T00:30:00","slug":"cansinobios-covid-19-mrna-vaccine-receives-approval-of-clinical-trial-application-in-china","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=7816","title":{"rendered":"CanSinoBIO’s COVID-19 mRNA Vaccine Receives Approval of Clinical Trial Application in China"},"content":{"rendered":"
<\/div>\n
\n

TIANJIN<\/span>, April 4, 2022<\/span> \/PRNewswire\/ — CanSino Biologics Inc. (“CanSinoBIO” of “the Company”) (SSE: 688185, HKEX: 06185) today announced that the National Medical Products Administration of China<\/span> (“NMPA”) granted approval for the clinical trial application of its COVID-19 mRNA vaccine in China<\/span>.<\/p>\n

Pre-clinical trial results showed that CanSinoBIO’s COVID-19 mRNA vaccine can induce high-titer neutralizing antibody levels against multiple SARS-CoV-2 variants of concern (“VOC”) identified by the World Health Organization (“WHO”), including the Omicron variant, a highly transmissible and the most dominant strain circulating in China<\/span> and globally. Additionally, results showed that CanSinoBIO’s mRNA vaccine can induce neutralizing antibodies with greater cross-reactivity against global VOCs and provide stronger protection against infections caused by the circulating variants, compared to the original strain-based COVID-19 vaccines.<\/p>\n

The clinical trial application of CanSinoBIO’s COVID-19 mRNA vaccine was filed by the Company and its subsidiary CanSino (Shanghai<\/span>) Biotechnology Co., Ltd (“CanSino Shanghai”). Established in July 2021<\/span>, CanSino Shanghai is focused on developing an mRNA technology platform and further strengthening the Company’s research and development (“R&D”) capabilities.<\/p>\n

Compared with traditional vaccine technology platforms, the mRNA technology platform has significant advantages in the R&D process and production cycles, including fast, scalable and uniform production. CanSinoBIO will continue to focus on developing a variety of innovative preventive vaccines in its diversified product pipeline with proprietary technologies, including the inhaled version of its COVID-19 vaccine, Convidecia\u2122. In December 2021<\/span>, the NMPA granted approval for CanSinoBIO’s MCV4 vaccine, Menhycia\u2122, making it the first of its kind to be authorized in China<\/span>.<\/p>\n

About CanSinoBIO
<\/b>Incorporated in 2009, CanSinoBIO (SSE: 688185, HKEX: 06185) commits to research, production and commercialization of innovative vaccines for China<\/span> and global public health security. It possesses five integrated platform technologies including viral vector-based technology, synthetic vaccine technology, protein structure design and recombinant technology, mRNA technology, as well as formulation and delivery technology. As of today, it has established a robust pipeline of 17 vaccines preventing 12 diseases, including the Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) conditionally approved in 2021, the Group A and Group C Meningococcal Conjugate Vaccine (CRM197) and the Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) approved in the same year. Additional information can be found online at www.cansinotech.com<\/a><\/p>\n<\/p><\/div>\n

Source: CanSino Biologics Inc.<\/p>\n","protected":false},"excerpt":{"rendered":"

TIANJIN, April 4, 2022 \/PRNewswire\/ — CanSino Biologics Inc. (“CanSinoBIO” of “the Company”) (SSE: 688185, HKEX: 06185) today announced that the National Medical Products Administration of China (“NMPA”) granted approval for the clinical trial application of its COVID-19 mRNA vaccine in China. Pre-clinical trial results showed that CanSinoBIO’s COVID-19 mRNA vaccine can induce high-titer neutralizing […]<\/p>\n","protected":false},"author":8,"featured_media":7817,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-7816","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business-news"],"yoast_head":"\nCanSinoBIO's COVID-19 mRNA Vaccine Receives Approval of Clinical Trial Application in China - My Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/transmediavictoria.net.au\/?p=7816\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CanSinoBIO's COVID-19 mRNA Vaccine Receives Approval of Clinical Trial Application in China - My Blog\" \/>\n<meta property=\"og:description\" content=\"TIANJIN, April 4, 2022 \/PRNewswire\/ — CanSino Biologics Inc. (“CanSinoBIO” of “the Company”) (SSE: 688185, HKEX: 06185) today announced that the National Medical Products Administration of China (“NMPA”) granted approval for the clinical trial application of its COVID-19 mRNA vaccine in China. Pre-clinical trial results showed that CanSinoBIO’s COVID-19 mRNA vaccine can induce high-titer neutralizing […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/transmediavictoria.net.au\/?p=7816\" \/>\n<meta property=\"og:site_name\" content=\"My Blog\" \/>\n<meta property=\"article:published_time\" content=\"2022-04-04T00:30:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2022\/04\/cansinobios-covid-19-mrna-vaccine-receives-approval-of-clinical-trial-application-in-china.png\" \/>\n\t<meta property=\"og:image:width\" content=\"144\" \/>\n\t<meta property=\"og:image:height\" content=\"100\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin_tony\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin_tony\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=7816#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=7816\"},\"author\":{\"name\":\"admin_tony\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"headline\":\"CanSinoBIO’s COVID-19 mRNA Vaccine Receives Approval of Clinical Trial Application in China\",\"datePublished\":\"2022-04-04T00:30:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=7816\"},\"wordCount\":375,\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=7816#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2022\\\/04\\\/cansinobios-covid-19-mrna-vaccine-receives-approval-of-clinical-trial-application-in-china.png\",\"articleSection\":[\"Business News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=7816\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=7816\",\"name\":\"CanSinoBIO's COVID-19 mRNA Vaccine Receives Approval of Clinical Trial Application in China - My Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=7816#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=7816#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2022\\\/04\\\/cansinobios-covid-19-mrna-vaccine-receives-approval-of-clinical-trial-application-in-china.png\",\"datePublished\":\"2022-04-04T00:30:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=7816#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=7816\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=7816#primaryimage\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2022\\\/04\\\/cansinobios-covid-19-mrna-vaccine-receives-approval-of-clinical-trial-application-in-china.png\",\"contentUrl\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2022\\\/04\\\/cansinobios-covid-19-mrna-vaccine-receives-approval-of-clinical-trial-application-in-china.png\",\"width\":144,\"height\":100},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=7816#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CanSinoBIO’s COVID-19 mRNA Vaccine Receives Approval of Clinical Trial Application in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\",\"name\":\"My Blog\",\"description\":\"My WordPress Blog\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\",\"name\":\"admin_tony\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"caption\":\"admin_tony\"},\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?author=8\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CanSinoBIO's COVID-19 mRNA Vaccine Receives Approval of Clinical Trial Application in China - My Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/transmediavictoria.net.au\/?p=7816","og_locale":"en_US","og_type":"article","og_title":"CanSinoBIO's COVID-19 mRNA Vaccine Receives Approval of Clinical Trial Application in China - My Blog","og_description":"TIANJIN, April 4, 2022 \/PRNewswire\/ — CanSino Biologics Inc. (“CanSinoBIO” of “the Company”) (SSE: 688185, HKEX: 06185) today announced that the National Medical Products Administration of China (“NMPA”) granted approval for the clinical trial application of its COVID-19 mRNA vaccine in China. Pre-clinical trial results showed that CanSinoBIO’s COVID-19 mRNA vaccine can induce high-titer neutralizing […]","og_url":"https:\/\/transmediavictoria.net.au\/?p=7816","og_site_name":"My Blog","article_published_time":"2022-04-04T00:30:00+00:00","og_image":[{"width":144,"height":100,"url":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2022\/04\/cansinobios-covid-19-mrna-vaccine-receives-approval-of-clinical-trial-application-in-china.png","type":"image\/png"}],"author":"admin_tony","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin_tony","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/transmediavictoria.net.au\/?p=7816#article","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/?p=7816"},"author":{"name":"admin_tony","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"headline":"CanSinoBIO’s COVID-19 mRNA Vaccine Receives Approval of Clinical Trial Application in China","datePublished":"2022-04-04T00:30:00+00:00","mainEntityOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=7816"},"wordCount":375,"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=7816#primaryimage"},"thumbnailUrl":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2022\/04\/cansinobios-covid-19-mrna-vaccine-receives-approval-of-clinical-trial-application-in-china.png","articleSection":["Business News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/transmediavictoria.net.au\/?p=7816","url":"https:\/\/transmediavictoria.net.au\/?p=7816","name":"CanSinoBIO's COVID-19 mRNA Vaccine Receives Approval of Clinical Trial Application in China - My Blog","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/#website"},"primaryImageOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=7816#primaryimage"},"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=7816#primaryimage"},"thumbnailUrl":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2022\/04\/cansinobios-covid-19-mrna-vaccine-receives-approval-of-clinical-trial-application-in-china.png","datePublished":"2022-04-04T00:30:00+00:00","author":{"@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"breadcrumb":{"@id":"https:\/\/transmediavictoria.net.au\/?p=7816#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/transmediavictoria.net.au\/?p=7816"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/transmediavictoria.net.au\/?p=7816#primaryimage","url":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2022\/04\/cansinobios-covid-19-mrna-vaccine-receives-approval-of-clinical-trial-application-in-china.png","contentUrl":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2022\/04\/cansinobios-covid-19-mrna-vaccine-receives-approval-of-clinical-trial-application-in-china.png","width":144,"height":100},{"@type":"BreadcrumbList","@id":"https:\/\/transmediavictoria.net.au\/?p=7816#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/transmediavictoria.net.au\/"},{"@type":"ListItem","position":2,"name":"CanSinoBIO’s COVID-19 mRNA Vaccine Receives Approval of Clinical Trial Application in China"}]},{"@type":"WebSite","@id":"https:\/\/transmediavictoria.net.au\/#website","url":"https:\/\/transmediavictoria.net.au\/","name":"My Blog","description":"My WordPress Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/transmediavictoria.net.au\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7","name":"admin_tony","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","caption":"admin_tony"},"url":"https:\/\/transmediavictoria.net.au\/?author=8"}]}},"_links":{"self":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/7816","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=7816"}],"version-history":[{"count":0,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/7816\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/media\/7817"}],"wp:attachment":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=7816"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=7816"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=7816"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}